263 related articles for article (PubMed ID: 22836659)
21. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
[TBL] [Abstract][Full Text] [Related]
22. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
[TBL] [Abstract][Full Text] [Related]
23. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse.
Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C
Front Genet; 2021; 12():705505. PubMed ID: 34447412
[TBL] [Abstract][Full Text] [Related]
24. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
Shi C; Hu B; Guo L; Cao P; Tian Y; Ma J; Chen Y; Wu H; Hu J; Deng L; Zhang Y; Yuan W
J Bone Miner Res; 2016 May; 31(5):1003-14. PubMed ID: 26679066
[TBL] [Abstract][Full Text] [Related]
25. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL
J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187
[TBL] [Abstract][Full Text] [Related]
26. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
[TBL] [Abstract][Full Text] [Related]
27. A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I.
Liu Y; Wang J; Liu S; Kuang M; Jing Y; Zhao Y; Wang Z; Li G
Bone; 2019 Oct; 127():646-655. PubMed ID: 31369917
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.
King D; Jarjoura D; McEwen HA; Askew MJ
J Bone Miner Res; 2005 Jun; 20(6):987-93. PubMed ID: 15883639
[TBL] [Abstract][Full Text] [Related]
29. Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis.
Joeng KS; Lee YC; Lim J; Chen Y; Jiang MM; Munivez E; Ambrose C; Lee BH
J Clin Invest; 2017 Jun; 127(7):2678-2688. PubMed ID: 28628032
[TBL] [Abstract][Full Text] [Related]
30. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading.
Spatz JM; Ellman R; Cloutier AM; Louis L; van Vliet M; Suva LJ; Dwyer D; Stolina M; Ke HZ; Bouxsein ML
J Bone Miner Res; 2013 Apr; 28(4):865-74. PubMed ID: 23109229
[TBL] [Abstract][Full Text] [Related]
31. Effect of rapamycin on bone mass and strength in the α2(I)-G610C mouse model of osteogenesis imperfecta.
Bateman JF; Sampurno L; Maurizi A; Lamandé SR; Sims NA; Cheng TL; Schindeler A; Little DG
J Cell Mol Med; 2019 Mar; 23(3):1735-1745. PubMed ID: 30597759
[TBL] [Abstract][Full Text] [Related]
32. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.
Oestreich AK; Carleton SM; Yao X; Gentry BA; Raw CE; Brown M; Pfeiffer FM; Wang Y; Phillips CL
Osteoporos Int; 2016 Jan; 27(1):161-70. PubMed ID: 26179666
[TBL] [Abstract][Full Text] [Related]
33. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
[TBL] [Abstract][Full Text] [Related]
34. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
35. Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Jeong Y; Rafique A; Krueger P; Kleiner S; Phillips CL
J Bone Miner Res; 2022 May; 37(5):938-953. PubMed ID: 35195284
[TBL] [Abstract][Full Text] [Related]
36. Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation.
Tamplen M; Fowler T; Markey J; Knott PD; Suva LJ; Alliston T
Head Neck; 2018 Jul; 40(7):1453-1460. PubMed ID: 29522281
[TBL] [Abstract][Full Text] [Related]
37. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
38. Modeling anabolic and antiresorptive therapies for fracture healing in a mouse model of osteogenesis imperfecta.
O'Donohue AK; Dao A; Bobyn JD; Munns CF; Little DG; Schindeler A
J Orthop Res; 2023 Apr; 41(4):808-814. PubMed ID: 35803595
[TBL] [Abstract][Full Text] [Related]
39. Solanum muricatum Ameliorates the Symptoms of Osteogenesis Imperfecta In Vivo.
Wang N; Wang L; Wang Z; Cheng L; Wang J
J Food Sci; 2019 Jun; 84(6):1646-1650. PubMed ID: 31116433
[TBL] [Abstract][Full Text] [Related]
40. Effect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta.
Tauer JT; Abdullah S; Rauch F
J Bone Miner Res; 2019 Feb; 34(2):207-214. PubMed ID: 30357929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
